Collegium Pharmaceutical (COLL) Finished Goods (2016 - 2025)

Collegium Pharmaceutical's Finished Goods history runs 10 years deep, the most recent figure standing at $20.2 million for Q3 2025.

• On a quarterly basis, Finished Goods rose 23.13% year-over-year to $20.2 million in Q3 2025; TTM through Sep 2025 was $20.2 million, a 23.13% increase from a year earlier, with the FY2024 full-year figure at $17.8 million, up 17.12% from the prior year.
• Finished Goods held at $20.2 million in Q3 2025 per COLL's latest filing, from $20.2 million in the prior quarter.
• Across five years, Finished Goods topped out at $36.9 million in Q1 2022 and bottomed at $9.5 million in Q2 2021.
• The 5-year median for Finished Goods is $15.2 million (2023), against an average of $16.5 million.
• Across the five-year window, Finished Goods surged 280.78% in 2022 and sank 62.81% in 2023, its largest moves.
• Year by year, Finished Goods stood at $12.7 million in 2021, then rose by 27.77% to $16.2 million in 2022, then decreased by 6.29% to $15.2 million in 2023, then grew by 17.12% to $17.8 million in 2024, then increased by 13.64% to $20.2 million in 2025.
• Per Business Quant, the three latest COLL Finished Goods figures stand at $20.2 million (Q3 2025), $20.2 million (Q2 2025), and $18.5 million (Q1 2025).